AGR2 and neoplasm: For instance, Roy et al. demonstrated an augmented tumor-killing effect by developing BsAb-AGR2×PD1 for AGR2-positive cancers, intercepting AGR2 paracrine signaling, and rerouting cytotoxic T-cells towards AGR2+ cancer cells to reduce tumor cell viability [135].